Nnit A/s · OMXCOP:NNIT
Nnit A/s — Q1 2022 Earnings Presentation
16 slides from Nnit A/s's earnings presentation, May 6, 2022
Slide 1: Q1 2022 webcast
1 Q1 2022 webcast CEO Pär Fors CFO Pernille Fabricius 6 May, 2022 1
Slide 2: Agenda
Agenda • Q1 highlights • Strategic update • Business Unit performance • Group financials • 2022 outlook • Q&A Disclaimer This presentation contains forward-looking statements including projections on future financial results. Statements regarding the future are subject to risks and uncertainties tha
Slide 3: Q1 highlights
Q1 highlights • Strategic transformation initiatives Revenue and operating margin on track to lift revenue and earnings 1000 6.6% 5.1% 5.0% 10 3.0% 500 0 • Temporary lower utilization 731 710 698 738 701 -1.3% 0 -10 • Effect of renegotiated infrastructure Q1-21 Q2-21 Revenue (DKKm) Q3-21 Q4-21 Q1-22
Slide 4: Strategic update
Strategic update FOCUS ORGANIZATION ACQUISITION Sharpened focus on New organizational prime4services acquisition growth and cost reduction and reporting structure boosts Production IT initiatives to bolster efficiencies and provide transparency CONSOLIDATION TRACTION INDEPENDENCY Global Delivery Cen
Slide 5: Life Sciences Solutions (LSS)
Life Sciences Solutions (LSS) • 19% growth mainly driven by Revenue and gross margin acquisitions 300 25.1% 20.5% 20.1% 30 17.3% 11.6% 200 10 • Organic growth and margins 100 167 166 191 199 198 impacted by a cancelled project 0 -10 Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Revenue (DKKm) Gross margin (%) • Pos
Slide 6: Cloud & Digital Solutions (CDS)
Cloud & Digital Solutions (CDS) • Results on par with Q1 2021 Revenue and gross margin 300 30 20.9% 17.1% 16.0% 16.4% 11.6% • Focus on Cloud services, Microsoft 200 10 Dynamics and SAP projects 100 211 213 199 225 213 0 -10 • ERP implementation project Q1-21 Q2-21 Revenue (DKKm) Q3-21 Q4-21 Q1-22 Gr
Slide 7: Hybrid Cloud Solutions (HCS)
Hybrid Cloud Solutions (HCS) • Expected decline in revenue and Revenue and gross margin margins after renegotiation of NNG 400 16.1% 13.0% 11.0% 9.9% 20 infrastructure agreement and end 10.3% 10 of SLA contract 200 353 331 308 314 290 0 0 -10 • 12% reduction of production costs Q1-21 Q2-21 Q3-21 Q4-
Slide 8: Group financials Q1 2022
Group financials Q1 2022 DKKm Q1 Q1 FY 2022 2021 2021 Revenue 701 731 2,878 28% Revenue growth -4.1% 1.2% 1.7% 42% Gross profit 44 100 345 Sales and marketing costs 32 30 124 30% Administrative expenses 21 21 80 Operating profit before special -9 48 142 items LSS CDS HCS Operating margin before spec
Slide 9: Unchanged 2022 outlook
Unchanged 2022 outlook • Strategic initiatives to spark growth and improve profitability • Contract wins and solid 2022 backlog • Growth in LSS and CDS, somewhat slower HCS due to lower project work volume Guidance 2022 outlook 2021 realized Revenue growth 2-5% 1.7% Operating profit margin Around 5%
Slide 10: Closing remarks
Closing remarks Increased guidance on revenue growth, while maintaining New organizational Key contracts won and 2022 outlook maintained structure to sharpen financialcontributing renewed guidance onto based on expected effects focus on growth and operating solid profit for order backlog of strategi
Slide 11: Q&A
Q&A NNIT
Slide 12: Contact information
Contact information Pernille Fabricius CFO PNFA@nnit.com Financial calendar 2022 Interim report Q2 August 12, 2022 Interim report Q3 November 2, 2022 12
Slide 13: We make a mark
We make a mark nnit.com ANIT
Slide 14: Appendix: Life Sciences Solutions
Appendix: Life Sciences Solutions DKKm Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Revenue 198 199 191 166 167 Life Sciences (excl. NGG) 170 175 166 145 146 - Life Sciences (Int.) 163 167 160 137 137 - Life Sciences (DK) 7 8 6 8 9 Novo Nordisk Group 28 24 24 20 20 Public 0 0 1 1 1 BU production costs 17
Slide 15: Appendix: Cloud & Digital Solutions
Appendix: Cloud & Digital Solutions DKKm Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Revenue 213 225 199 213 211 Life Sciences (excl. NGG) 35 40 31 35 32 - Life Sciences (Int.) 11 17 12 16 8 - Life Sciences (DK) 24 23 19 19 24 Novo Nordisk Group 23 23 21 22 25 Enterprise 106 111 101 101 98 Public 40 41
Slide 16: Appendix: Hybrid Cloud Solutions
Appendix: Hybrid Cloud Solutions DKKm Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Revenue 290 314 308 331 353 Life Sciences (excl. NGG) 39 45 48 53 49 - Life Sciences (Int.) 14 15 15 12 13 - Life Sciences (DK) 25 30 33 41 36 Novo Nordisk Group 89 107 98 108 113 Enterprise 81 83 81 85 80 Public 24 25 25